Yidu Tech, Inc.

Yidu Tech, Inc.

HHKEX:2158
2.88
HKD
+0.06
(+2.13%)
5.01BMarket Cap
Nov 20Next Earn
Yidu Tech, Inc.
HKEX:2158
(Hong Kong Exchange)

Recent

price

2.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
CNY
0.03
0.11
1.38
1.7
1.29
0.81
0.77
0.68
0.78
- -
Revenue per Share
-1.08
-1.04
-3.74
-7.24
-0.8
-0.63
-0.19
-0.11
0.07
- -
Basic EPS, GAAP
-0.21
-0.47
-0.97
-0.69
-0.71
-0.38
-0.35
-0.33
-0.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.38
-2.53
-4.13
5.11
4.04
3.94
3.79
3.69
3.57
3.57
Book Value per Share
-1.38
-2.56
-4.17
5.07
4.01
3.9
3.75
3.66
3.53
3.53
Tangible Book Value per Share
902
902
404
511
958
995
1,052
1,056
1,049
1,066
Basic Weighted Avg Shares
23
102
558
867
1,237
805
807
715
819
- -
Sales/Revenue/Turnover
-1,076.02
-423.19
-104.08
-48.54
-58.34
-74.45
-43.66
-42.96
-7.79
- -
Operating Margin (%)
22
33
37
36
47
46
47
43
37
- -
Depreciation Expense
-978
-934
-1,510
-3,700
-762
-628
-195
-118
73
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
6.13
- -
Effective Tax Rate (%)
-4,304.87
-915.17
-270.55
-426.77
-61.62
-78.04
-24.15
-16.47
8.87
- -
Profit Margin (%)
505
441
-2,246
4,736
3,941
3,840
3,780
3,331
2,174
2,174
Working Capital
271
375
508
7
26
5
6
6
32
32
LT Debt
-1,245
-2,278
-3,726
4,752
4,007
4,156
4,092
3,978
3,703
3,703
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
2.19
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
1.74
- -
Return on Capital (%)
- -
- -
- -
- -
-17.49
-15.56
-4.81
-2.97
1.92
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
124
126
39
LT Borrowings
- -
- -
27
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,063
1,064
1,020
Market Capitalization
6,136
6,422
4,406

Working Capital

CNY

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
3,967
2,868
2,745
Cash, Cash Equivalents & STI
3,296
2,201
2,099
Accounts Receivable, Net
449
429
378
Inventories
13
35
5
Total Current Liabilities
636
648
571
Payables & Accruals
- -
- -
- -
ST Debt
124
126
39
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-4.64%
-6.9%
Free Cash Flow
- -
-8.49%
-85.28%
Net Income, GAAP
- -
-73.46%
-161.73%
Sales/Revenue/Turnover
- -
2.24%
14.59%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
807
2025
- -
- -
715
2026
- -
- -
819

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.19
2025
- -
- -
-0.11
2026
- -
- -
0.07

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Yidu Tech Inc engages in providing healthcare solutions powered by artificial intelligence and big data technology. The company's core products and services include the Big Data Platform and Solutions, which offers medical data intelligence and analytics-driven clinical development, real-world study and evidence, and digital commercialization solutions primarily to pharmaceutical, biotech, and medical device companies; the Life Sciences Solutions segment delivering clinical development support, real-world evidence, digital commercialization solutions, and pharmaceutical product sales; and the Health Management Platform and Solutions segment operating YiduCore, an AI medical brain that extracts, structures and standardizes raw medical data into actionable insights, along with health management platform services, insurance product distribution, personalized digital therapies, and out-of-hospital care services. Yidu Tech operates primarily in China, serving top hospitals, regulators, policymakers, pharmaceutical, and insurance sectors. Founded in 2014 and headquartered in Beijing, the company also integrates its proprietary AI middleware widely across leading Grade III-A hospitals. Recent major developments include Yidu Tech achieving its first full-year profit on adjusted EBITDA in fiscal year 2024 driven by operational efficiencies and business growth, with total revenue reaching RMB 807.1 million and a gross profit margin increase to 42.1%. The company deepened its engagement in AI healthcare innovation by co-building an AI Healthcare Innovation Hub and expanding its client base among top hospitals and policymakers, while continuing to enhance its YiduCore AI medical brain capabilities. Yidu Tech also completed share award grants under its Post-IPO scheme to drive long-term growth and has seen strong revenue growth in its Big Data Platform and Life Sciences segments, reflecting a strategic focus on integrating AI across healthcare services, pharmaceuticals, insurance, and patient care to optimize the healthcare value chain comprehensively. Yidu Tech targets a broad range of healthcare market participants including hospitals, pharmaceutical companies, biotech firms, insurance companies, and regulators, delivering end-to-end AI-powered medical data intelligence and health management services. The company remains focused on expanding industry applications and scaling its AI-driven healthcare ecosystem across China, leveraging proprietary algorithms and strategic partnerships to enhance precision medicine and healthcare accessibility. Its integrated approach combines digital healthcare platforms, real-world evidence, clinical research solutions, and personalized health management tools, positioning Yidu Tech as a leading player in AI-enabled healthcare innovation in the region.